Skip to content

Menu

LexBlog, Inc. logo
NetworkSub-MenuBrowse by SubjectBrowse by PublisherJoin the NetworkGet StartedSubscribeSupportContact
Search
Close

340B Program Alert: Despite Recent Setbacks, HRSA Continues to Advance Potential 340B Rebate Model Pilot

By Brenda Maloney Shafer, Richard Davis, Michael French & Jake Pallotta on February 17, 2026
Email this postTweet this postLike this postShare this post on LinkedIn

A little over a month after a federal circuit court blocked the Health Resources and Services Administration’s (HRSA) scheduled implementation of its 340B Rebate Model Pilot Program largely due to procedural deficiencies, HRSA appears to be performing additional diligence in hopes of avoiding similar setbacks in the future. In an announcement on February 13, 2026, HRSA released a request for information (RFI) seeking stakeholder feedback on the potential impact of rebate models in the 340B Program space.1

As part of the RFI, HRSA is inviting stakeholder commentary regarding several rebate-related issues, including medication access concerns, anticipated cash-flow impacts, proposed alternatives and scope-limiting measures to inform the rebate pilot design, among others. Many requests expressly seek submission of detailed data to demonstrate expected impacts and operational costs, signaling HRSA’s intent to conduct a more detailed and granular review of its proposed model this time around. Stakeholder comments to the RFI must be submitted and received no later than March 19, 2026.

Notably, the RFI comes just two days after the White House’s Office of Management and Budget (OMB) completed its regulatory review of HRSA’s new 340B rebate proposal – which also occurred over the span of just a few days. Although no material steps toward implementation are expected until the conclusion of the comment period, the quick advancement of HRSA’s RFI suggests a sense of urgency in advancing a new rebate model proposal.

For additional background information regarding the initial 340B rebate model proposal, please review our earlier publications on this subject, available on our 340B Blog. Given the significant implications for both manufacturers and covered entities, we will continue to closely monitor activity related to the RFI and provide additional updates as necessary. In the meantime, if you have questions or require assistance in developing responsive comments to the RFI, please reach out to your Quarles attorney or:

  • Brenda Maloney Shafer: 602-229-5774 / brenda.shafer@quarles.com
  • Richard Davis: 414-277-5844 / richard.davis@quarles.com
  • Michael French: 312-715-5261 / michael.french@quarles.com
  • Jake Pallotta: 317-399-2810 / jake.pallotta@quarles.com

END NOTES


1 340B Rebate Model Pilot Program – Request for Information, Health Resources and Services Administration, available here. Note that the RFI will be formally published in the Federal Register on February 17, 2026.

Photo of Brenda Maloney Shafer Brenda Maloney Shafer

Brenda is a member of Quarles & Brady’s Health Law Practice Group. Her practice focuses primarily in health law and, in particular, health care regulatory and transactional work. Along with her law degree, she holds a Master’s of Law in Health Law. A…

Brenda is a member of Quarles & Brady’s Health Law Practice Group. Her practice focuses primarily in health law and, in particular, health care regulatory and transactional work. Along with her law degree, she holds a Master’s of Law in Health Law. A particular area of focus is counseling clients regarding compliance with the 340B Drug Pricing Program.

Read more about Brenda Maloney ShaferEmailBrenda Maloney's Linkedin Profile
Show more Show less
Photo of Richard Davis Richard Davis

Richie has extensive experience with the 340B Program and has worked with both contract pharmacies and covered entities to develop and optimize their program participation. His practice also focuses on a wide variety of pharmacy regulatory issues, including controlled substances and state licensure…

Richie has extensive experience with the 340B Program and has worked with both contract pharmacies and covered entities to develop and optimize their program participation. His practice also focuses on a wide variety of pharmacy regulatory issues, including controlled substances and state licensure compliance.

Read more about Richard DavisEmailRichard's Linkedin Profile
Show more Show less
Photo of Michael French Michael French

Mike has unique experience in the 340B Program, utilizing his former 340B consulting background to blend legal analysis with operational and financial considerations. Mike has assisted an extensive list of 340B stakeholders optimize available 340B benefit while ensuring compliance with the 340B Program’s…

Mike has unique experience in the 340B Program, utilizing his former 340B consulting background to blend legal analysis with operational and financial considerations. Mike has assisted an extensive list of 340B stakeholders optimize available 340B benefit while ensuring compliance with the 340B Program’s complex regulatory structure.

Read more about Michael FrenchEmailMichael's Linkedin Profile
Show more Show less
Photo of Jake Pallotta Jake Pallotta
Read more about Jake PallottaEmail
  • Posted in:
    Health Care and Life Sciences
  • Blog:
    To Be or Not to 340B Blog
  • Organization:
    Quarles & Brady LLP
  • Article: View Original Source

Call us at 1-800-913-0988 or email sales@lexblog.com.

Facebook LinkedIn Twitter RSS
The Library at LexBlog
  • About LexBlog
  • The Field We Built
  • Library at LexBlog
  • Our Beliefs
  • Our Team
  • Contact LexBlog
  • Disclaimer
  • Editorial Policy
  • Terms of Service
  • Get Started
  • Publishing Solutions
  • Compass
  • Submit a Request
  • Support Center
  • System Status
Copyright © 2026, LexBlog, Inc. All Rights Reserved.
Law blog design & platform by LexBlog LexBlog Logo